Analysts predict multi-billion dollar growth in Indonesian pharma

24 February 2016

Indonesia’s rapidly-growing pharmaceutical market will reach $12.6 billion by 2020, up from $7 billion in 2015, industry analysts have predicted.

Research and consulting firm GlobalData said the surge, which has seen the sector double in size over the last six years, is driven primarily by the Indonesian government’s economic and healthcare initiatives.

And it looks set to be further boosted by the establishment of a universal healthcare scheme, known as the Jaminan Kesehatan Nasional, which was launched in January 2014 to provide health insurance to 250 million Indonesians by 2019 when it will become the world’s largest social health insurance.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK